Schizoaffective disorder in women with childbearing potential: Focus on treatment with newer and emerging psychotropic agents

Schizoaffective Disorder: New Research

Volumn , Issue , 2006, Pages 187-220

  Gentile, Salvatore ^a  

^a ASL Salerno 1   (Italy)

Author keywords

Antidepressants; Antiepileptic drugs; Atypical antipsychotics; Breastfeeding; Lactation; Mood stabilizers; Pregnancy; Schizoaffective disorder

Indexed keywords

EID: 53649109790     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (213)

1. Benabarre A, Vieta E, Colom F, Martinez-Aran A, Reinares M, Gasto C. Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiological, clinical and prognostic differences. Eur Psychiatry. 2001; 16 (3): 167-72.
2. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003; 28 (4 Suppl 2): 17-54.
3. Marneros A. Schizoaffective disorder: clinical aspects, differential diagnosis, and treatment. Curr psychiatry Rep. 2003; 5: 202-205.
4. Howard ML, Kumar C, Leese M, Thornicroft G. The general fertility rate in women with psychotic disorders. Am J Psychiatry. 2002; 159: 991-997.
5. Bathia T, Franzos MA, Wood JA, Nimgaonkar VL, Deshpande SN, Gender and procreation among patients with schizophrenia. Schizophr Res. 2004 ; 68 (2): 387-394.
6. Kornstein SG. Gender, depression, and antidepressant treatment. Primary Psychiatry. 2003; 10 (12): 58-61.
7. McCandless F, Sladen C. Sexual health and women with bipolar disorder. J Adv Nurs. 2003; 44 (1): 42-48.
8. Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull. 1997; 23 (4): 623-635.
9. Raja M, Azzoni A. Sexual behavior and sexual problems among patients with severe chronic psychoses. Eur Psychiatry. 2003; 18 (2): 70-76.
10. Butterfield MI, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC, Goodman, LA and the Five-Site Health and Risk Study Research Committee. Blood-Borne Infections and Persons With Mental Illness: Gender Differences in Hepatitis C Infection and Risks Among Persons With Severe Mental Illness. Psychiatr Ser. 2003; 54: 848-853.
11. Allison DB, Fontaine KR, Moonseong H, et al: The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry. 1999; 60: 215-220.
12. Eckert LO, Sugar N, Fine D. Characteristics of sexual assault in women with a major psychiatric diagnosis. American Journal of Obstetrics and Gynaecolog. 2002; 186:1284-1291.
13. Oates M. Perinatal maternal mental health services. Royal College of Psychiatrists, Special Interest Group, Council Report CR88, April 2000.
14. Craig T, Bromet EJ. Parents with psychosis. Ann Clin Psychiatry. 2004; 16 (1): 35-9.
15. Niemi L, Suvisaari JM, Haukka JK, Wrede G, Lonnquist JK. Cumulative incidence of mental disorders among offspring of mothers with psychotic disorder. Br J Psychiatry. 2004; 185: 11-17.
16. Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull. 2003; 67: 219-29.
17. McElroy SL, Keck PE jr, Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry. 1999; 60 (suppl 5): 16-21.
18. Royal College of Obstetricians and Gynaecologist. Why mothers die 1997-1999: The fifth report of the Confidential Enquires into Maternal Deaths in the United Kingdom. London: RCOG; 2001.
19. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156 (8):1138-48.
20. Barnas C, Bergant A, Hummer M, Saria A, Fleishhacker WW. Clozapine concentrations in maternal and foetal plasma, amniotic fluid and breast milk [letter]. Am J Psychiatry. 1994; 151: 945.
21. Tenyi T, Trixler M, Vereczkey G, Dorka A. Use of clozapine during pregnancy. Orv Heti. 1994; 135: 1967-1969.
22. Jones LY ed. Clozapine in treatment-resistant schizophrenia: a scientific update. London, England 1992; Royal Society of Medicine.
23. Nguven HN, Lalonde P. Clozapine and pregnancy. Encéphale. 2003; 29 (2): 119-124.
24. Dev V, Krupp P. The side effects and safety of clozapine. Rev Contemp Pharmacother. 1995; 6: 197-208.
25. Bazire S. Psychotropic Drug Directory 2003/04. The professionals' pocket handbook & aide memoire. Published by Fivepin Publishing Limited, Salisbury 2003:p 252.
26. Di Michele V, Ramenghi LA, Sabatino G. Clozapine and lorazepam administration in pregnancy [letter]. Eur Psychiatry. 1996; 11: 214.
27. Stoner SC, Somni RW jr, Marken PA, Anya I, Vaughn J. Clozapine use in two fullterm pregnancies [letter]. J Clin Psychiatry. 1997; 58: 364-365.
28. Devinsky O, Pacia SV. Seizures during clozapine treatment. J Clin Psychiatry. 1994; 55 (9, suppl B): 153-156.
29. Baker RW, Chengappa KN. Gastroesophageal reflux as a possible result of clozapine treatment [letter]. J Clin Psychiatry. 1998; 59: 257.
30. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003; 15 (1): 33-48.
31. Ernst LC, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002; 63 (suppl 4): 42-55.
32. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000; 20: 399-403.
33. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O. et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005; 66 (4): 444-9.
34. Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry. 2006; in press.
35. Ely Lilly Research Laboratories. Data on file.
36. Wilson DR, D'Souza LD, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2002; (59): 1-6.
37. Patton SW, Misri S, Corral MR, Perry KF, Kuan AJ. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can J Psychiatry. 2002; 47: 959-965.
38. Gentile S. Atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. 2004; 38 (7-8): 1265-1271.
39. Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and the nursing period [letter] . J Clin Psychiatry. 2002; 63 (1): 76-7.
40. Hill RC, Mc Ivor RJ, Wojnar-Horton RE, Hackett LP, Ilett KF. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol. 2000; 20: 285-6.
41. Ilett KF, Hackett LP, Kristensen JH, Vaddadi KS, Gardiner SJ, Begg EJ, Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother. 2004; 38 (2): 273-6.
42. Aichhorn W, Stuppaeck C, Whitworth AB. Risperidone and breast-feeding. J Psychpharmacol. 2005; 19 (2): 211-13.
43. Balke LD. Quetiapine is effective in the treatment of bipolar affective disorder during pregnancy. Poster presented at 7th World Congress of Biological Psychiatry, Berlin, 2001 1-6 July.
44. Tényi T, Trixler M, Keresztes Z. Quetiapine and pregnancy [letter]. Am J Psychiatry. 2002; 159 (4): 674.
45. Pace A, D'Agostino F. Quetiapina in gravidanza: caso clinico (Italian). Gio Ital Ost Ginecol. 2003; 9: 381-5.
46. Taylor TM, 'O Toole MS, Ohlsen RI, Walters J, Pilowsky LS. Safety of quetiapine during pregnancy [letter]. Am J Psychiatry. 2003; 160 (3): 588-9.
47. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Use of polypharmacotherapy in pregnancy: a prospective outcome in a case. Progr Neuropsychopharmacol Biol Psychiatry. 2004; 28 (3): 603-5.
48. Lee A, Giesbrecht E, Dunn E, Ito S. Excretion of quetiapine in breast milk. Am J Psychiatry. 2004; 161 (9): 1715-6.
49. Gentile S. Quetiapine-fluvoxamine combination in pregnancy and breastfeeding. Arch Women's Mental Health. 2006; in press.
50. Mendhekar DM, Sharma JB. Use of aripiprazole during late pregnancy in a woman with psychotic illness. Ann Pharmacother. 2006; 40: 575.
51. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. 2005; 28 (2): 137-152.
52. Hallberg P, Siöblom V. The use of selective reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Pharmacol. 2005; 25 (1): 59-73.
53. Diav-Citrin O, Schechtman S, Weinbaum D, Arnon J, Di Gianantonio E, Clementi M, Ornoy A. Paroxetine and fluoxetine in pregnnacy: a multicenter, prospective, controlled study. Reprod Toxicol. 2005; 20: 459.
54. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996; 10 (4): 285-294.
55. Lexapro PDR Tablets Information. Available on: www.antidepressantsfacts.com/ lexapro.htm. Accessed: January 26, 2005.
56. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996; 335 (14): 1010-1015.
57. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003; 188 (3): 812-815.
58. Pitfield SF, Oberlander TF, Fitzgerald CE, Tsang AO, Junker A. Prolonged prenatal psychotropic medication exposure reduces T-helper (CD4+) cells in neonates at birth [Abstract]. Pediatr Res. 2000; 47 (4 Pt2): 76A.
59. Oberlander TF, Grunau RE, Fitzgerald C, Misri S, Riggs W. Prenatal psychotropic medication exposure alters acute neonatal pain response [Abstract]. Pediatr Res. 2000; 47 (4 Pt2): 31A.
60. Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W. Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics. 2005; 115 (2): 411-425.
61. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002; 156 (11): 1129-1132.
62. Nordeng H, Lindemann R, Permikov KV, et al. Neonatal withdrawal syndrome after in utero exposure to Selective Serotonin Reuptake Inhibitors. Acta Paediatr. 2001; 90 (3): 288-291.
63. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study of newer antidepressant concentration in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol. 2004; 7 (3): 329-334. Epub 2004 Mar 22.
64. Laine K. Neonatal adverse events associated with in utero exposure to SSRI/SNRI. Available on: www.fda.gov/ohrms/dockets/ac/04/slides/2004-404051_11_Levin.ppt. Accessed January 7, 2005.
65. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry. 1995; 3: 412-413.
66. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 1997; 391-392.
67. Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Foetal Neonatal Ed. 2001; 2: F134-135.
68. Zeskind PS, Stephens LE. Association of maternal-SSRI use during pregnancy and disrupted neonatal sleep organization [Abstract]. Pediatr Res. 2003; 53 (4 Pt2):71A.
69. Morag I, Batash D, Keidar R, Bulkowstein M, Heyman E. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol. 2004; 42 (1): 97-100.
70. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993; 5: 721-722.
71. Santos RP, Pergolizzi JJ. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft®). J Perinatol. 2004; 24 (6): 392-394.
72. Campino GA. Cardiac arrhythmia in a newborn associated with fluoxetine use during pregnancy [letter] . Ann Pharmacother. 2002; 36 (3): 533-534.
73. Oca MJ, Donn SM. Association of maternal sertraline (Zoloft) therapy and transient neonatal nystagmus. J Perinatol. 1999; 6 (pt 1): 460-461.
74. Loriedo C, Di Fabio F, Vella G. Effetti collaterali degli SSRI. In: Gli SSRI nella pratica clinica. Masson S.p.A. ed. Milano; 2001: p 122.
75. Alderman CP, Seshadri P, Ben Tovim DI. Effects of serotonin reuptake inhibitors on haemostasis. Ann Pharmacother. 1996; 30: 1232-1234.
76. Mhanna JM, Bennerr II JB, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics. 1997; 100: 158-159.
77. Salvia Roiges MD, Garcia L, Gonge Mellgren et al. Neonatal convulsions and subarachnoid haemorrhage after in utero exposure to paroxetine. Rev Neurol. 2003; 8: 724-726.
78. Vanhaesebrouck P, De Bock F, Zecic A, De Praeter C, Smets K, De Coen K, et al. Phototherapy-mediated syndrome of inappropriate secretion of Antidiuretic Hormone in an in utero selective serotonin reuptake inhibitor-exposed infant. Pediatrics. 2005; 115 (5): e508-e511.
79. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotoninergic symptoms in newborns and cord blood monoamine and prolactine concentrations. Arch Gen Psychiatry. 2003; 60 (7): 720-726.
80. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hypochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993; 32 (6): 1253-1255.
81. Hale TW, Shurm S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr. 2001; 40: 681-684.
82. Chambers CD, Anderson PO, Thomas RG, Dick LM, Felix RJ, Johnson KA, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics. 1999; 104 (5): e61.
83. Shmidt K, Olesen OV, Jensen PN. Citalopram and breastfeeding: serum concentration and side effects in the infant. Biol Psychiatry. 2000; 47 (2): 164-165.
84. Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol. 1999; 4: 521-527.
85. Piontek CM, Wisner KL, Perel JM, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2002; 2: 111-113.
86. Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimating of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry. 2002; 52 (5): 42-47.
87. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry. 2001; 50 (10): 775-782.
88. Heikkinen T, Ekbald U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003; 73 (4): 330-337.
89. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion, and effects in breastfed infants. Br J Clin Pharmacol. 2000; 50 (3): 263-268.
90. Nulman I, Koren G. The safety of fluoxetine during pregnancy. Teratology. 1996; 53: 304-308.
91. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, et al. Neurodevelopment of children exposed in utero to antidepressant drug. New Engl J Med. 1997; 336 (4): 258-262.
92. Mattson S, Eastvold A, Jones K, Harris J, Chambers C. Neurobehavioral follow-up of children prenatally exposed to fluoxetine [Abstract] . Teratology. 1999; 59: 376.
93. Morison SJ, Grunau RE, Oberlander TF, Misri S, Pannikar H, Reebye P. Infant social behavior and development in the first year of life following prolonged prenatal psychotropic medication exposure [Abstract]. Pediatr Res. 2001; 49 (4 Pt2): 28A
94. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout foetal life: a prospective, controlled study. Am J Psychiatry. 2002; 159 (11): 1889-1895.
95. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004; 65 (2): 230-237.
96. Gentile S. SSRIs in pregnancy and lactation. Emphasis on neurodevelopmental outcome. CNS Drugs. 2005; 19 (7): 623-33.
97. Ruchkin V, Martin A. SSRIs and the developing brain. Lancet. 2005; 5 (9458): 451-3.
98. Ilett KF, Hackett PC, Kristensen JH, Rampono J, Rolland K. Estimation of infant dose and assessment of breastfeeding safety for escitalopram. Poster presented at International Congress of Therapeutic Drug Monitoring & Clinical Toxicology. Louisville (Kentucky), USA. April 23-28, 2005.
99. Kesim M, Yaris F, Kadioglu M, Yaris E, Kalioncu NI, Ulku C. Mirtazapine use in two pregnant women. Is it safe? [letter] . Teratology. 2002; 66: 204.
100. Saks BR. Treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases. Arch Women Mental Health. 2001; 3 (4): 165-170.
101. Aichhorn W, Whitworth AB, Weiss U, Stuppaek C. Mirtazapine and breast-feeding [letter]. Am J Psychiatry. 2004; 161 (12): 2325.
102. Sinclair J, Birtwistle J, Baldwin D. The tolerability of venlafaxine. Rev Contemp Pharmacother. 1998; 9: 333-344.
103. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001; 158: 1728-1730.
104. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis (May). Ann Pharmacother. 2005; 39 (5): 803-809.
105. de Moor RA, Mourad L, ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneesked. 2003; 147 (28): 1370-1372.
106. Sanz EJ, De-las Cuevas C, Kiuru A, Bate A, Edwards R. Selective reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005; 365 (9458): 482-487.
107. Ilett KF, Hackett LP, Dusci LJ, Roberts MJ, Kristensen JH, Paech M, Groves A, Yapp P. Distribution and excretion of venlafaxine and O-desmethilvenlafaxine in human milk. Br J Clin Pharmacol. 1998; 45 (5): 459-462.
108. Gentile S, de Bartolomeis A, Muscettola G. Farmaci psicotropi di II generazione: possibilità e limiti di utilizzo in gravidanza ed allattamento. Giorn Ital Psicopat. 2000; 6 (1): 62-78.
109. Reboxetine. Drug monograph, May 2000. Available on www.reboxetine.com/ prescribe/index.htlm. Accessed: January 26, 2005.
110. Einarson A, Koren G. New antidepressants in pregnancy. Can Fam Physician. 2004; 50 (2): 227-229.
111. Boshier A, Wilton LV, Shaikir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol. 2003; 59 (10): 767-773.
112. Chun-Fai-Chan B, Koren G, Fayez I, Karla S, Voyer-Levigne S, Boshier A, Shakir S, Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective-comparative study. Am J Obstet Gynecol. 2005; 192 (3): 932-936.
113. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: a case of possible infant seizure [letter]. J Clin Psychiatry. 2004 ; 65 (6): 881-882.
114. Cunnington CM, Tennis P, and the International Lamotrigine Pregnancy Registry Scientific Advisor Committee. Neurology. 2005; 64: 955-60.
115. Sabers A, Dam M, a-Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scandin. 2004; 109: 9-13.
116. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian Registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci. 2003; 10 (5): 543-549.
117. Tomson T, Battino D, Bonizzoni E, Craig J, Londhout D, Perucca E, Saberd A, Vajda F on behalf of the Collaborative EURAP Study Group. EURAP: an International Registry of Antiepileptic drugs and Pregnancy. Epilepsia. 2004; 45 (11): 1464.
118. Vajda FJE, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand. 2005; 112: 137-143.
119. Morrow JI, Russell A, Gutherie E, Parson L, Robertson I, Waddel R, Irwin B, Morrison P, McGivern C, Craig J. Malformation risks of anti-epileptic drugs in pregnancy; a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2005; Sep 12 [Epub ahead of print]
120. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000; 41 (6): 709-713.
121. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav. 2004; 5 (1): 102-105.
122. Gentile S. Lamotrigine in pregnancy and lactation [letter]. Arch Women's Mental Health. 2005; 8 (1): 57-58.
123. Friis ML, Kristensen O, Boas J, Dalby M, Deth SM, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993; 87: 224-227.
124. Andermann E. Pregnancy and oxcarbazepine [Discussant statement]. Epilepsia. 1994; 35 (suppl 3): S26.
125. Rabinowicz AL, Meishen Guiser R, D'Giano CH, Ferraro SM, Carranzana EJ. Report of a single-centre pregnancy registry of AEDs: focus on outcomes with oxcarbazepine (Trileptal®). Epilepsia. 2002; 43 (suppl 7): poster 2.232.
126. Peltola JT, Kaartinen M, Uoitila J. Oxcarbazepine (Trileptal ®) and pregnancy outcomes: report of a single-centre, retrospective study. Poster presented at the 7th European Congress of the European Federation of Neurological Society, Helsinki, August 30-September 2, 2003: poster 318.00.
127. Isojarvi JIT, Artama M, Auvinen A. Pregnancy outcome in women taking oxcarbazepine for epilepsy. Poster presented at the 7th European Congress of the European Federation of Neurological Society, Helsinki, August 30-September 2, 2003: poster 321.00.
128. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav. 2004; 5 (2): 163-167.
129. Lassiter A, Mamie MM, Cid R, Rivière ME. Pregnancy outcomes with oxcarbazepine (Trileptal?) therapy: a review of Novartis safety database. 6th European Congress on Epileptology, Vienna, Austria, May 30-June 3, 2004.
130. Jedrzejczak J, Greese-Lyko M. Evaluation of teratogenic effects of new generation of antiepileptic drugs. Epilepsia. 2002; 43 (suppl 8): 158 [P508] .
131. Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin. 2005; 21 (5): 693-701.
132. Bulau P, Paar WD, Von Unruh GE. Pharmacokinetics of oxcarbazepine and 10-hidroxy-carbazepine in the newborn child of oxcarbazepine treated mother. Eur J Clin Pharmacol. 1998; 34: 311-313.
133. Gentile S. Oxcarbazepine (Tolep®) in pregnancy and lactation [letter]. Clin Drug Inv. 2003; 23 (10): 687.
134. Gentile S. Infant neurodevelopment following pre-and postnatal exposure to oxcarbazepine. Poster presented at XIII World Congress of Psychiatry, 10-15 September 2005, Cairo (Egypt). P.103.00
135. Gentile S. The safety of new mood stabilizers in pregnancy and lactation [Abstract]. Eur J Neuropsychopharmacol. 2004; 14 (suppl 3): S324-S325.
136. Ohman I, Vitols S, Luef G, Soderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation and in the neonate: preliminary observations. Epilepsia. 2002; 43 (10): 1157-1160.
137. Davson SI. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer. 2004; 100: 149-155.
138. Lawrence R. A review of the medical benefits and contraindications to breastfeeding in the United States. Maternal & ChildHealth Technical Information Bulletin. Arlington Va: National Center for Education in Maternal and Child Health; 1997.
139. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schafer C, Garbis H, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005; 66 (3): 317-22.
140. Brown CS. Depression and anxiety disorders. Obstet Gynecol Clin North Am. 2001; 28: 241-268.
141. Altshuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and postpartum period. J Clin Psychiatry. 1998; 59 (suppl 2): 29-33
142. Gentile S. SSRIs and venlafaxine-induced discontinuation syndrome. Poster presented at 18th Congress European College of Neuropsychopharmacology, Amsterdam (The Netherlands), 22-25 October 2005. P.2.001.
143. Kallen B. Fluoxetine use in early pregnancy. Birth Defects Res B Dev Reprod Toxicol. 2004; 71 (6): 395-396.
144. Edward GJ, Anderson I. Systematic review and guide to selective serotonin reuptake inhibitors. Drugs. 1999; 57 (4): 507-533.
145. Stahl SM. Mechanism of action of selective serotonin reuptake inhibitors. Serotonin receptor pathways mediate therapeutic effects and side effects. J Affect Dis. 1998; 51: 215-235.
146. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol. 1996; 11: 273-278.
147. Food and Drug Administration. A summary basis of approval for Paxil (paroxetine). Food and Drug Administration Freedom of Information Department, Rocksville, 1993.
148. Agreen H, Aberg-Wistedt A. Sertraline vs paroxetine in major depression. A multicenter, double-blind, 24 weeks comparison [Abstract]. New research abstracts American Psychiatric Association Annual Meeting, Toronto, 1998.
149. Sivojelezova A, Shuhaiber S, Sarkissian S, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005; 193: 2004-2009.
150. Bazire S. Psychotropic drug directory 2001/02. The professionals' pocket handbook & aide memoire. Quay Books Division, Mark Allen Publishing Ltd, Salisbury, 2001: p 162.
151. Gagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res. 1993; 4: 145-152.
152. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2005; 293 (19): 2372-2383.
153. Wen SW, Yang Q, Garner P, Olatunbosum O, Nimrod C, Walker M. Selective reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006; 194: 961-966.
154. Gentile S. Escitaopram late in pregnancy and during breastfeeding. Ann Pharmacother. 2006; in press.
155. Gunduz H, Woerner MG, Alvir JM, Degreef G, Lieberman JA. Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects. Schizophr Res. 1999; 40 (3): 237-243.
156. Howard LM, Goss C, Leese M, Thornicroft G. Medical outcome of pregnancy in women with psychotic disorders and their infants in the first year after birth. Br J Psychiatry. 2003; 182: 63-67.
157. Epperson R, Czarkowski KA, Ward-O Brien D, Weiss E, Gueorguieva R, Jatlow P, Anderson GM. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry. 2001; 158 (10): 1631-1637.
158. Chung MY, Min KH, Jun YJ, Kim SS, Kim WC, Jun EM. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004 ; 19 (7): 489-494.
159. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002; 14 (3):175-182.
160. Iqbal MM, Gundlapalli SP, Ryan WG, Ryals T, Passman TE. Effect of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants. South Med J. 2001; 94: 304-322.
161. Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol. 2005; 18: 135-40.
162. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of literature. Am J Genet A. 2005; 132A (4): 441-444.
163. Vieta E, Sanchez-Moreno J, Goikolea JM, Colom F, Martinez-Aran A, Benabarre A, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol. 2004; 24 (4): 374-378.
164. Nickel MK, Nickel C, Mitterlehner FO, Triit K, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a doubleblind, placebo-controlled study. J Clin Psychiatry. 2004; 65 (11): 1515-1519.
165. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine in bipolar disorder. Drugs. 2003; 63 (19): 2029-50.
166. Food and Drug Administration. Efficacy Supplements Approved in Calendar Year 2004. Available on: http://www.fda.gov/cder/rdmt/ESCY04AP.htm. Accessed: May, 2004.
167. Reiff-Elridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews SB, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol. 2000; 182: 159-163.
168. Physician's Desk Reference. Montale, NJ: Medical Economics; 2001.
169. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000; 41 (6): 709-713.
170. Rambeck B, Kurlermann G, Stodieck SR, et al. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol. 1997; 51: 481-484.
171. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology. 2002; 59: 251-255.
172. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005; Aug 3; [Epub ahead of print]
173. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry. 2000; 61 (2): 79-90.
174. Hirschfeld RM, Kasper S. A review of the evidence for carbazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 2004; 30: 1-16.
175. Hellewes JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord. 2002; 72: s23-34.
176. Benedetti A, Lattanti L, Pini S, Musetti L, Dell'Osso L, Cassano GB. Oxcarbazepine as an add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord. 2004; 79 (1-3): 273-277.
177. Bruno MK, Harden CL. Epilepsy in pregnant women. Curr Treat Options Neurol. 2002; 4 (1): 31-40.
178. Smith PEM, for the UK Oxcarbazepine Advisory Board. Clinical recommendations for oxcarbazepine. Seizure. 2001; 10: 87-91.
179. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005; Mar 1 [Epub ahead of print]
180. Kalra S, Born L, Sarkar M, Einarson A. The safety of antidepressant use in pregnancy. Expert Opin Drug Saf. 2005; 4 (2): 273-84.
181. Nordeng H, Spigset O. Treatment with selective reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005; 28 (7): 565-81.
182. Dawes SD. Can SSRIs reduce the risk of preeclampsia in pregnant, depressed patients? Med Hypotheses. 2005; 64 (1): 33-36.
183. Levey L, Ragan K, Hower-Hartley A, Newport DJ, Stowe ZN. Psychiatric disorders in pregnancy. Neurol Clin. 2004; 22 (4): 863-893.
184. Baethge C. Long-term treatment of schizoaffective disorder: review and recommendations. Pharmacopsychiatry. 2003; 36: 45-56.
185. Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy. Am J Psychiatry. 2005; 162 (11): 2162-70.
186. Moore NA, Calligaro DO, Wong BT, et al. The pharmacology of olanzapine and other new antipsychotics agents. Curr Opin Invest Drugs. 1993; 2: 281-293.
187. Dewey KG, Heinig MJ, Nommsen LA. Maternal weight-loss patterns during prolonged lactation. Am J Clin Nutr. 1993; 58: 162-166.
188. Short R. What the breast does for the baby, and what the baby does for the breast. Aust N Z J Obstet Gynaecol. 1994; 23: 262-264.
189. Campbell C. Brestfeeding and health in the western world. Br J Gen Pract. 1996; 46: 613-617.
190. Davis M, Savitz D, Graubard B. Infant feeling and childhood cancer. Lancet. 1988; 2: 365-368.
191. Rubin ET, Lee A, Ito S. When breastfeeding mothers need CNS-acting drugs. Can J Clin Pharmacol. 2004; 11 (2): e257-266.
192. Brockington I. Postpartum psychiatric disorders. Lancet. 2004; 363 (9405): 303-310.
193. Gentile S. The role of estrogen therapy in postpartum psychiatric disorders: an update. CNS Spectr. 2005; 10(12): 944-52.
194. Born L, Zinga D, Steiner M. Challenges in identifying and diagnosing postpartum disorders. Primary Psychiatry. 2004; 11 (3): 29-36.
195. Rapkin AJ, Mikacich JA, Moatakef-Imani B. Reproductive mood disorders. Primary Psychiatry. 2003; 10 (12): 31-40.
196. Riordan D, Appleby L, Faragher B. Mother-infant interaction in post-partum women with schizophrenia and affective disorders. Psychol Med. 1999; 29 (4): 991-995.
197. Niemi L. Offspring of mothers with psychotic disorder: childhood development and adulthood psychiatry morbidity. Available on:http://www.ktl.fi/attachments/suomi/ julkaisut/juljaisutsusarja_a/2004a18.pff. Accessed August 11, 2005
198. Nicholson J, Biebel K, Hinden B, Henry A, Stier L. Critical issues for parents with mental illness and theyr family. Draft prepared for Mental Health Services Research. Massachusetts University, 2000.
199. Reproductive Health Outlook. Gender and sexual health. Available on: http://www. rho.org/html/gendersexualhealth.htm. Accessed: August 15, 2005.
200. Australian Infant, Child, Adolescent, and Family Mental Health Association. Children of Parents with a Mental Illness (COPMI) Initiative. Principles and action for services and people working with children of a parent with mental illness. Commonwealth Department of Health and Ageing. Draft for consultation prior September, 2003.
201. Llewellyn A, Stowe ZN, Strader JR jr. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry. 1998; 59 (suppl 6): 57-64.
202. Gentile S. More than half of women with a history of psychosis have a psychiatric episode in the first year after childbirth [Invited commentary]. Evidence-Based Mental Health. 2005; 32 (3): 33.
203. Hiday VA, Swartz MS, Swanson JW, Borum R, Wagner HR. Impact of outpatient commitment on victimization of people with severe mental illness. Am J Psychiatry. 2002; 159: 1403-1411.
204. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004; 30 (2): 255-64.
205. Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003; (64 supp16): 3-9.
206. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303-19.
207. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med. 2005. 353 (12): 1209-1223.
208. Howard L, Shah N, Salmon M, Appleby L. Predictors of social services supervision of babies of mothers with mental illness after admission to a psychiatric mother and baby unit. Soc Psychiatry Psychiatr Epidemiol. 2003; 38 (8): 450-455.
209. Miller LJ, Finnerty M. Sexuality, pregnancy, and childrearing among women with schizophrenia-spectrum disorders. Psychiatry Serv. 1996; 47 (5): 502-506.
210. Schooler NR, Relapse and re-hospitalisation: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003: 64 Suppl.16:14-17
211. Howard L. Psychotic disorders and parenting -The relevance of patients' children for general adult psychiatric services. Psychiatr Bull. 2000; 24: 324-326.
212. Poinso F, Gay MP, Glangeaud-Freudenthal NM, Rufo M. Care in mother-baby psychiatric unit: analysis of separation at discharge. Arch Women Ment Health. 2002; 5 (2): 49-58.
213. Salmon M, Abel K, Cordingley L, Friedman T, Appleby L. Clinical and parenting skills outcomes following joint mother-baby psychiatric admission. Aust N Z J Psychiatry. 2003; 37 (5): 556-562.